Breaks Categories: News

FridayMay 31, 2024 3:46 pm

BioMedNewsBreaks — Biomerica Inc. (NASDAQ: BMRA) Announces Agreement in $5.5M At-the-Market Offering

Biomerica (NASDAQ: BMRA), a biomedical technology company that develops, patents, manufactures and markets advanced diagnostics and therapeutic products, has entered into an at-market issuance sales agreement with EF Hutton LLC and R.F. Lafferty & Co. Inc. According to the company, the agreement is related to BMRA common stock shares. The company filed a prospectus supplement on May 10, 2024. EF Hutton is serving as sales agent to Biomerica in connection with the $5.5 million at-the-market offering. “In accordance with the terms of the sales agreement, we may offer and sell shares of our common stock pursuant to this prospectus having…

Continue Reading

WednesdayMay 29, 2024 1:42 pm

BioMedNewsBreaks — Predictive Oncology Inc. (NASDAQ: POAI) CEO to Participate at Upcoming BIO International Convention 2024

Predictive Oncology (NASDAQ: POAI), a leader in artificial-intelligence (“AI”)-driven drug discovery and biologics, will be spotlighted at next month’s BIO International Convention 2024. The conference is scheduled for June 3–6, 2024, in San Diego. According to the announcement, Predictive Oncology CEO Raymond Vennare will be presenting a company overview at the gathering. His presentation, titled “Novel AI Driven Insights to Guide Early Drug Discovery,” is slated to begin at 6:45 EDT on June 3, 2023. “We are very pleased to participate in this year’s Bio International Convention, which is the premier gathering of biopharmaceutical stakeholders from around the world,” said…

Continue Reading

WednesdayMay 29, 2024 11:23 am

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Submission of Clinical Trial Protocol for Unbuzzd(TM) Study

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, has submitted a clinical trial protocol to assess the safety and efficacy of Unbuzzd(TM) in healthy volunteers. The clinical trial protocol for the METAL-2 trial will be reviewed by the U.S. institutional review board. After receiving approval, the company will begin recruiting healthy volunteers for the study, which is designed to evaluate the ability of Unbuzzd to help alleviate the effects of acute alcohol intoxication. “We are thrilled that we have reached…

Continue Reading

TuesdayMay 28, 2024 2:32 pm

BioMedNewsBreaks – HealthLynked Corp. (HLYK) Launches Innovative, AI-Powered Chat Function

HealthLynked (OTCQB: HLYK), a leading innovator in healthcare technology, today unveiled its new AI-powered chat function designed to assist patients in finding healthcare providers across the country. The new AI chat bot will significantly enhance the effectiveness of the HealthLynked Concierge Team, reducing wait times and offering 24/7 service to users. The advanced feature will provide instant answers to customer questions as well as assist in locating healthcare providers by name, specialty or location. “Our new AI chat function is a testament to our commitment to leveraging cutting-edge technology to improve healthcare accessibility,” said Dr. Michael Dent, CEO of HealthLynked.…

Continue Reading

TuesdayMay 28, 2024 1:31 pm

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Issues Update on NIH-Funded Program for CNM-Au8® in ALS

Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced several key updates on its National Institutes of Health (“NIH”) funded Accelerating Access to Critical Therapies Expanded Access Program for CNM-Au8® compassionate use (“EAP”) in ALS. Late last year, in collaboration with Columbia University and Synapticure, Clene announced the award of a four-year grant from the National Institute of Neurological Disorders and Stroke (“NINDS”), part of the NIH, to support an EAP for Clene’s investigational…

Continue Reading

TuesdayMay 28, 2024 9:34 am

BioMedNewsBreaks — FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Enters IR Agreement with IR Agency

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions, has entered into an investor relations services agreement with IR Agency LLC. According to the announcement, the agreement, which was effective May 22, 2024, outlines IR Agency’s responsibilities to communicate information about FSD Pharma to the financial community. That information could include company profiles and media distribution as well as building a digital community. The agreement is for one month, with services beginning on May 28, 2024; the contract notes that FSD Pharma will pay a fee of…

Continue Reading

WednesdayMay 22, 2024 2:44 pm

BioMedNewsBreaks — SOHM, Inc. (SHMN) Continues to Advance Groundbreaking Technology

SOHM (OTC: SHMN), a leading generic pharmaceutical and upstart biotechnology company, today announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. The technology holds the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The revolutionary new ABBIE system, due to SOHM’s committed, consistent and focused approach by lead scientists at its lab at UACI in Tucson, Arizona, is due to be sold as off-the-shelf kits in the third quarter of this year. “We are…

Continue Reading

TuesdayMay 21, 2024 1:27 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, will be spotlighted in an upcoming webinar, hosted by RedChip Companies. The event is slated for May 30, 2024, and will begin at 4:15 p.m. ET. Nutriband chair Serguei Melnik and CEO Gareth Sheridan will present during the event, which will provide key information for investors regarding current operations and upcoming milestones. To register for the event, visit https://ibn.fm/9REfQ To view the full press release, visit https://ibn.fm/mH9jC About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development…

Continue Reading

MondayMay 20, 2024 2:09 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Positive Study Data for Its AI Program

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel of heart rhythm cardiologists in detecting atrial flutter. Key findings from the analysis show that HeartBeam AI combined with VCG outperformed an expert panel reviewing single-lead ECGs and demonstrated a statistically significant 6% improvement in the detection of atrial flutter cases compared to an expert panel reviewing 12-lead ECGs. “The modern vectorcardiogram is nearly 100 years old, and yet we are cautiously…

Continue Reading

MondayMay 20, 2024 1:17 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company Showcase

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners. Climaco’s presentation is slated to begin at 1:40 p.m. ET on May 21, 2024. A live webcast will be available on the Events page of CNSP’s website. To view the full press release, visit https://ibn.fm/TQeLP About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company…

Continue Reading